The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...

An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...

Pfizer Inc. (PFE) announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization ...

Pfizer's focus should remain on existing cost realignment plans and pipeline investments. Read why my investment thesis ...

COVID-19 2024–2025 vaccines are recommended for everyone aged 6 months and older, with vaccines targeting the JN.1 and KP.2 strains of SARS-CoV-2.

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 21. David Risinger ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) voted 14–1 in favor of expanding the agency’s guidance for ...

NEW YORK — U.S. health officials on Wednesday recommended that people 50 and older get a shot against bacteria that can cause ...

Pfizer slashed its production targets for its COVID-19 vaccine because of a lack of raw materials for its supply chain, according to press reports. The big pharma has said in recent weeks that it ...